Research on chemotherapy and its side effects. Covers nerve-injury prevention, gold-nanorod therapy, less-intensive regimens, and combination treatments.
Researchers at the University of Iowa report improved survival rates for women with stage IV breast cancer using a four-drug, high-dose chemotherapy treatment followed by a bone marrow transplant. The study found an overall survival rate of 38 percent, compared to projected rates of 32-30 percent in other studies.
Researchers developed CMA-676, an antibody-drug conjugate targeting AML cells while sparing normal blood cells. The treatment produces mild side effects and induces remission comparable to standard chemotherapy regimens.
A combination of radiation and chemotherapy treatment significantly increased overall survival in esophageal cancer patients, with 22% surviving at least eight years after treatment. The study found that this combined therapy was associated with longer survival compared to radiation therapy alone.
Researchers at UNC Chapel Hill have discovered a novel cancer gene therapy strategy that blocks NF-kappa B, a protein that enables many cultured tumor cells to escape death. The technique showed promising results in mice with human tumors, shrinking and eliminating tumors in some cases.
Researchers at Penn discovered that chemoembolization doubles the survival time of adult patients with colon cancer that has spread to the liver. The procedure, which delivers chemotherapy directly to tumor cells, outperforms systemic chemotherapy in managing metastasized disease.
A landmark study involving women with invasive cervical cancer showed that adding chemotherapy to radiation therapy significantly improves survival rates and disease-free survival. The study found that 73% of patients who received both treatments survived for at least five years, compared to 58% of those given only radiation.
Researchers found that an experimental antibiotic, moxifloxacin, is effective against a range of drug-resistant bacterial strains, including those resistant to penicillin and erythromycin. The findings suggest it could be a potential treatment for serious and deadly illnesses caused by Streptococcus pneumoniae bacteria.
Researchers at the University of Maryland Medical Center have discovered a cancer resistance protein that rapidly pumps out chemotherapy from breast cancer cells. This finding may lead to new strategies to reverse resistance to cancer-fighting drugs, improving treatment outcomes for patients.
A new experimental compound, CMA-676, demonstrates promising efficacy in treating acute myelogenous leukemia (AML) with an antibody-targeted chemotherapy approach. The treatment shows a remission rate of approximately 40% comparable to standard combination chemotherapy regimens.
Toxicologists have made a groundbreaking discovery that chemical compounds formed during the reaction of free radicals with human tissue can be detected in the urine within just a few days. This breakthrough has the potential to provide an earlier indication of the damaging effects of chemotherapy on cancer patients.
The study aims to scientifically evaluate the benefits of a Chinese herbal formula in alleviating multiple side effects of chemotherapy in early-stage breast cancer patients. Participants will receive either the herbal formula or a placebo, with their progress monitored over 180 days.
Researchers discovered specific genetic changes that indicate whether chemotherapy is effective in treating patients with anaplastic oligodendrogliomas. The discovery allows for immediate determination of chemotherapy response at diagnosis, offering improved treatment options for patients.
A large-scale randomized study found that chemotherapy improves long-term survival for women under 50 and those in their 50s and 60s, even if the cancer has not spread. The treatment also showed benefits for women without evidence of disease spread.
Researchers at Oregon Health & Science University have found that treatment with sodium thiosulfate significantly reduces hearing loss in brain tumor patients receiving carboplatin chemotherapy. This breakthrough could help combat the hearing loss associated with platinum-based chemotherapy treatment for other types of cancer.
A synthetic detergent, nonylphenolethoxylate (NPE), commonly used in household cleansers, has been discovered to block a drug pump in cancer cells, reducing the need for chemotherapy drugs. The researchers found NPE present in human urine and suggest it could be a useful adjunct to standard treatments.
BioNumerik's novel chemoprotecting agent BNP7787 appears to completely protect against major toxicities associated with widely used platinum anticancer drugs. The company's Karenitecins demonstrate potent oral antitumor activity and bypass common drug resistance mechanisms.
Duke researchers have identified a lung condition in breast cancer patients that can limit therapy choices if not treated promptly. The disorder, DPTS, is successfully treated with inexpensive corticosteroids, improving pulmonary function by 17%.
Researchers at St. Jude Children's Research Hospital are developing new brain tumor treatment protocols that use 3D imaging to accurately target tumors, reducing radiation doses and side effects. The protocols involve combining lower-dose radiation with chemotherapy to increase survival rates and minimize long-term damage.
The MiCK assay measures how light scatters off of leukemia cells to determine the effectiveness of drugs being used to attack the cells. This technique allows for more accurate identification of which drugs will be most effective for each patient, revolutionizing leukemia therapy.
Researchers developed a synthetic human hormone that triples platelets received from each donor, improving recovery of platelets in patients undergoing chemotherapy. An increased supply would give physicians more options for treating chemotherapy patients and make transfusions more affordable.
The study reveals that a low-dose pretreatment with certain DNA-crosslinking agents can temporarily suppress P-glycoprotein production, increasing the sensitivity of drug-resistant cells to chemotherapy. This approach may increase the efficacy of cancer chemotherapy in patients and minimize drug interactions.
Researchers at University at Buffalo and Roswell Park Cancer Institute found no link between chemotherapy use and cancer risk in children's offspring. The study analyzed health records of 153 children born to 91 chemotherapy patients, showing none developed cancer.
AmBisome, a liposomal formulation of amphotericin B, has been shown to sterilize the CSF significantly earlier than conventional amphotericin B, with at least equal clinical efficacy and lower nephrotoxicity. In a randomized multi-center study, low-dose AmBisome therapy produced a response rate of 68% in treating invasive aspergillosis.
Duke University researchers identify a new target for stopping drug resistance in cancer cells by targeting the cellular pump that expels chemotherapy drugs. The study found that certain immunosuppressive drugs can block this pump by removing a vital activator, FKBP12, allowing chemotherapy drugs to be effective.
Researchers at Georgia Institute of Technology have developed a new method to examine and quickly map how nucleic acid ligands bind to and alter DNA at the molecular level. This allows for direct visualization of individual DNA molecules, providing crucial information on drug binding and mode of action.
Scientists have detailed the structure of yeast topoisomerase II, a key player in cell division. This knowledge could lead to the development of new anticancer drugs that target this enzyme. The discovery also has implications for the design of antimicrobial drugs and the treatment of cancer.